Long-Acting Contraception for the Developing World
|
|
- Byron Turner
- 5 years ago
- Views:
Transcription
1 April 18, 2017 Long-Acting Contraception for the Developing World Greg Kopf FHI360 GSK-CRS Long-Acting Injectables and Implantables Conference Philadelphia, PA
2 FHI 360: A Comprehensive Approach to Human Development (Originally the International Fertility Research Program-1971) Education Civil Society + Peacebuilding Economic Development + Livelihoods Health Gender Equality Nutrition Environment Research Technology Social Marketing + Communications Youth 2
3 THE PROBLEM: Expanding access to contraception: The need is urgent. 225 million women in developing countries have an unmet need for contraception Global Impact: 80 million unintended pregnancies in 2012 Roughly 303,000 maternal deaths* in 2015 Photo: Claudia Napoli via Flickr from * 3
4 Cancer 8.2 million c a Guttmacher Institute (2012 Abortion/Maternal Deaths in Context with Cardiovascular and Cancer Deaths Abortion/Maternal Deaths in Developing Countries (2012) a Maternal deaths 0.3 million Abortion 49.6 million Global Deaths (2012) Cardiovascular Disease 17.5 million b b WHO Fact Sheet (2016) c ACS, Global Cancer Fact & Figures (2015) 4
5 ANOTHER PROBLEM: Financial Commitment: Contraceptive R&D Investment in Context In 2013: Globally, $63 million was invested in contraceptive R&D Policycures, 2014 Meanwhile In 2015, Americans spent $6.9 billion on Halloween $350 million on costumes for their pets 5
6 Reasons for Unmet Need Reasons for Unmet Need There is a need to expand the method mix 6
7 Family Planning is a Cost-Effective Intervention that can Substantially Improve Health Millennium Development Goal 5b: By 2015, achieve universal access to reproductive health, including contraceptives If unmet need for contraception met: Prevent over 70% of unintended pregnancies Prevent 25% of maternal deaths Avert almost 75% of abortions $1.00 spent on contraception = $1.47 saved in maternal and newborn health care costs Sources: Guttmacher, UNFPA, WHO; Population Reference Bureau; BMGF; Halperin et al., Prevent 20% of newborn deaths Among HIV+ women, if unmet need were met, over 90,000 infant HIV infections averted 7
8 London Summit on Family Planning July 2012 Mobilized governments, international agencies, civil society organizations, foundations, and the private sector to commit to dramatically expanding access to voluntary family planning Goal of FP2020: Expand access to family planning to 120 million additional women in the world s 69 poorest countries by yplanning2020.org/ UK Government Bill & Melinda Gates Foundation UNFPA USAID Others 8
9 The Need for Newer Technologies in the Contraceptive Space Existing methods do not meet the needs of all Methods based on old technologies; there have been significant scientific advancements Some methods are difficult to use consistently and correctly High typical use failure rates High discontinuation Side effects or fear of side effects Changing needs and desires over reproductive lifespan Missing a spectrum of male methods Enhance competition and reduce costs These needs are cited for both the developing and developed worlds 9
10 Contraception Market and Scientific Evolution TIME Choice / Mode of Action Hormonal (female/ male) Combined Steroid Formulations Contraception Paradigm Shifts Hormonal (female) Steroid Receptor Modulators Hormonal (male) Steroid Receptor Modulators Hormonal (female) Non-Steroid Based Non-Hormonal (female) Novel follicular, oocyte and ovulation genes Non-Hormonal (male) Novel spermatogenesis, germ cell, epididymal and sperm cell genes Selectivity / Specificity 10
11 Contraceptive Technology Innovation Initiative at FHI360 Department Goals Focusing on longer-acting family planning methods, we Develop and evaluate new contraceptive technologies to expand the existing method mix Refine existing methods to make them more acceptable, accessible, and affordable Support efforts to get products introduced at public sector pricing in FP 2020 countries to better meet the changing reproductive needs of women and couples, especially those living in low-resource settings
12 Contraceptive Technology Innovation Initiative: Bridges multiple R&D stages and focuses on longer-acting approaches KEY FUNDING CTI Initiative Sino-implant (II) Longer Acting Injectable Envision FP KEY FUNDERS Bill & Melinda Gates Foundation NICHD (collaboration) USAID Early R&D Development Preclinical Clinical Phase I Clinical Phase II Clinical Phase III Regulatory Approval Intro/ Scale-up Global collaboration Cross-cutting research (acceptability, market pricing, registration, introduction) Knowledge sharing 12
13 Leveraging FHI 360 s Broad Experience Base FP commodity quality assurance; training and implementing global product quality standards Market assessments, developing service delivery tools, supporting policy/program change Product Introduction Product Quality Compliance Lab Clinical Research Decades of global technical leadership. Preferred PDP provider for implementing Phase II-III trials in developing countries Quantitative and qualitative research, including acceptability work Formative assessments, program evaluations, cost effectiveness studies to improve service delivery systems Social & Behavioral Research Operations Research Contraceptive Technology Innovation Biostatistics and Data Management Regulatory Affairs Innovative approaches for data management and analysis Experience in meeting rigorous regulatory requirements given developing country realities Together, we believe we represent the largest, deepest team of researchers focused on family planning method research and contraceptive innovation
14 What Technologies Might We Envision? On-demand methods for infrequent sex Non-surgical permanent contraception Reversible male options Multipurpose technologies (e.g., with HIV treatment) Biodegradable implants Unique delivery systems User-controlled toggle methods 14
15 Key Target Product Profile (TPP) Attributes Product-dependent duration of efficacy (1-6 months; 18 months; 5 years; 15 years) Product-dependent release profile (e.g., zero order release profile) Lowest safe and effective dose Side effect profile (no worse than current products) Additional health benefits Rapid and predictable return to fertility Acceptable Removable (product-dependent) Easy administration (lower level healthcare workers; self) Simplicity of presentation (e.g., single vial vs. multi component) Discreet No sharps waste (product-dependent) Stability (no cold chain) [Stable 3 years under Zone 4b conditions] Low cost (for procurement agencies) 15
16 Positive Impact of TPP on Procurement Agencies, Target Country Health Systems and End Users Product cost Avoidance of stock outs through extended product stability Simplicity of presentation Compatibility with existing products (e.g., implants compatible with existing trocars) Lower level healthcare worker administration or selfadministration Extended duration of efficacy would reduce rate of end user time, travel costs and return to clinic Increased compliance and continuation rates Products that permit appropriate birth spacing
17 Contraceptive Technology Innovation Initiative Pipeline Biodegradable implants Longer-Acting Injectables Single Rod Implant BMGF CTII USAID EnvisionFP Sino-implant (II) Alternative LNG- IUS in Kenya Early R&D Development Preclinical Clinical Phase I Clinical Phase II Clinical Phase III Regulatory Approval Intro/ Scale-up Microneedles Nonsurgical permanent contraception Microneedles Low dose DMPA Sayana Press Extension Comparative trial of alternative copper IUDs Acceptability research Over 75 organizations engaged including product development scientists, universities, pharmaceutical companies, service delivery groups and government agencies. 17
18 Progestins of Interest Levonorgestrel Etonogestrel Progesterone Nestorone Medroxyprogesterone Acetate
19 Schematic Comparison of Contraceptive Pharmacokinetics Predictable tail contraceptive effectiveness range
20 Biodegradable Microneedles Partners: Mark Prausnitz (Georgia Tech); Steven Schwendeman (Michigan) API: Levonorgestrel (LNG); Etonogestrel (ENG); Nestorone (NES) Delivery: PLA:PLGA microneedles containing API or microsphereloaded API; intradermal Target Contraceptive Duration: 1 month or longer Properties: Discreet self-administration Reduced pain Benefits to supply chain storage and distribution Microneedles that separate from patch upon application No sharps waste B C 20
21 Long Acting Injectable Partner: Linglin Feng (Shanghai Institute of Planned Parenthood Research) API: Levonorgestrel (LNG) Delivery: Microspheres (PLGA; PLGA:PLA) ; SQ Target Contraceptive Duration: 6 months Properties/Activities: Release duration tailored through changes in polymer composition Injectable through a 23-gauge needle Minimal release tail observed in rats QC of key materials Sterilization optimization Optimization of formulation/process Scale up Pilot scale study Further stability testing 21
22 Biodegradable Implant Partner: Mark Saltzman, Yale University API: Levonorgestrel (LNG) Delivery: Poly(ω-pentadecalactone-co-p-dioxanone) [poly(pdl-co-do)] implant Target Contraceptive Duration: 18 months Properties/Activities: In vitro release rates can be tuned through various fabrication methods and drug loading In vitro release demonstrate near zero order release rates and comparable to a commercial LNG implant Mouse biocompatibility study completed and positive Rat PK studies ongoing Implant removability/implant site histology to be examined Exploring core-shell options to reduce initial burst and shorten tail 22
23 Biodegradable Implant Partner: Gesea, ph Sciences API: Etonogestrel (ENG) Delivery: Cholesterol-based pellet implant Target Contraceptive Duration: 18 months Properties/Activities: Inexpensive materials Simple production Validating various in vitro dissolution assays In vivo study to evaluate erosion and ENG release from different monolithic and core/shell pellets Stability and sterilization studies underway 23
24 Biodegradable Implant Partner: Buddy Ratner (U. Washington) API: Levonorgestrel (LNG) Delivery: Biodegradable hydrogel rod containing 3 types of microspheres encased in a sheath biocompatible with tissue Target Contraceptive Duration: 18 months Properties/Activities: Sheath elicits a vascularized, non-fibrotic biointegration into subcutaneous tissue In vitro LNG release testing of the microspheres Fabricating hydrogel rods containing microspheres Development of an accelerated in vitro release method Further refining microsphere fabrication protocols 24
25 Sino-implant (II) Registration Status March 2015 Registered under multiple trade names: Zarin, Femplant, Trust, Simplant Bolivia Fiji Burkina Faso Ghana Cambodia Guatemala Chile* Indonesia China Jamaica Ethiopia** Kenya Madagascar Registered (n=26) Malawi Mali Mongolia Mozambique Nepal* Nigeria Pakistan Senegal Sierra Leone Uganda Vietnam Zambia Zanzibar Under review in over 10 additional countries Distributed by Marie Stopes International (MSI); Distributed by Pharm Access Africa Ltd. (PAAL) * Distributed by WomanCare Global ** Distributed by DKT International Distributed by APROFAM 25
26 1 Million units distributed to date in countries supported under project Impact of Sino-implant II According to the MSI Impact Calculator: 1.4 million unintended pregnancies averted Over 3000 maternal deaths averted Over 175,000 abortions averted In addition, units translate into $10.5 million units in commodity cost savings* Savings mean that an additional 1.3 million units of Sino-implant (II) could have been purchased *Impact is estimated based on distribution of 1,000,100 units. Savings are based on a price of US$8 per unit for Sino-implant (II), assuming the alternative would have been to purchase Jadelle. The average price for Jadelle was US$24 in 2009, US$22 in 2010, US$19 in 2011, US$18 in 2012, and $8.50 in 2013 and beyond according to information from the RHSC ( 26
27 Key Milestones Contraceptive Implant Prices : Changes Since Global Introduction of Sino-implant (II) $30 $25 $20 Jadelle Implanon Sino-implant (II) $15 $ prices based on weighted averages from RH Interchange in Kenya, Ethiopia and Sierra Leone prices from RHSC and press releases issued by the manufacturers $5 Prices established through volume guarantees last through 2018 $ : Sino-implant (II) registered in Kenya under trade name Zarin; first registration outside of Asia : Under agreement with partners, Merck/MSD reduces price of Implanon to $18/unit, with retro-active reduction to $16.50 when volume thresholds reached in Dec : Bayer HealthCare reduces price of Jadelle to $19/unit and then subsequently to $18/unit : Bayer HealthCare and Merck/MSD lower the prices of Jadelle and Implanon to US$8.50 per unit as part of volume guarantees : Over 1 million Sino-implant (II) units procured in countries under Gates initiative since 2009, resulting in over $10 million in commodity savings 27
Beginning with the End in Mind: Multiple Meanings for Contraceptive Research & Development. Kate Rademacher, Technical Advisor, FHI 360
Beginning with the End in Mind: Multiple Meanings for Contraceptive Research & Development Kate Rademacher, Technical Advisor, FHI 360 Begin with the end in mind in order to achieve Availability Quality
More informationThe Contraceptive Implant: Global Evidence & Marie Stopes International s Experience. Martyn Smith 6 th September 2012
The Contraceptive Implant: Global Evidence & Marie Stopes International s Experience Martyn Smith 6 th September 2012 Contraceptive Unmet Need in India 31million women in India still have an unmet need
More informationSino implant (II) Increasing Access by Introducing a Low Cost Contraceptive Implant
Sino implant (II) Increasing Access by Introducing a Low Cost Contraceptive Implant Markus J. Steiner, Diane Luo, Aida M. Cancel, David Jenkins, David Asante, Heather Vahdat, Haizhen Meng ICFP: Research
More informationAn Illustrative Communication Strategy for Contraceptive Implants
An Illustrative Communication Strategy for Contraceptive Implants: Step 1 (Analyze the Situation) 1 An Illustrative Communication Strategy for Contraceptive Implants Step 1: Analyze the Situation Health
More informationSupporting Agency Coordination and Cooperation in the Development of Contraceptive Methods Appropriate for Provision and Use in Low Resource Settings
Supporting Agency Coordination and Cooperation in the Development of Contraceptive Methods Appropriate for Provision and Use in Low Resource Settings Judy Manning, PhD Office of Population & Reproductive
More informationHormonal Implants Technical Update June 23, Jeff Spieler Senior Technical Advisor for Science and Technology GH/PRH
Hormonal Implants Technical Update June 23, 2009 Jeff Spieler Senior Technical Advisor for Science and Technology GH/PRH TOPICS: Elements of Successful FP Programs LAPMs Implants Introduction to the Implant
More informationPrivate Sector Opportunities to Support Family Planning and Access to Reproductive Health Services
Private Sector Opportunities to Support Family Planning and Access to Reproductive Health Services March 1, 2017 10:00 AM 11:00 AM ET Expert Connections Webinar in partnership with United Nations Population
More informationContraceptive Security for Long-Acting and Permanent Contraception (LA/PMs), & the Compelling Case for the Postpartum IUD
Contraceptive Security for Long-Acting and Permanent Contraception (LA/PMs), & the Compelling Case for the Postpartum IUD Roy Jacobstein, MD, MPH, and Jane Wickstrom, MA, EngenderHealth Global Health Mini-University,
More informationScaling-Up Excellence
Our global partnership: a balanced portfolio of country programmes We have developed a balanced portfolio of country programmes, which will allow us to maximise the global impact of our Partnership. Foundation
More informationIntroducing the Contraceptive Sino Implant II (Zarin) in Sierra Leone. Background
Introducing the Contraceptive Sino Implant II (Zarin) in Sierra Leone Background Maternal mortality in Sierra Leone is amongst the highest in the world. A decade-long civil war and severe underdevelopment
More informationMeeting Unmet Need and Increasing Contraceptive Options and Services with Postpartum Family Planning
Meeting Unmet Need and Increasing Contraceptive Options and Services with Postpartum Family Planning Roy Jacobstein, MD, MPH EngenderHealth FIGO panel, Post-partum contraception with a focus on post-partum
More informationImpactNow Kenya: Near-Term Benefits of Family Planning
ImpactNow Kenya: Near-Term Benefits of Family Planning Currently in Kenya 3.9 The number of children the average woman will have in her lifetime 1 in 5 Married women (18%) who do not want to have a child
More informationFamily Planning: Succeeding in Meeting Needs To Make a Better World. Amy Tsui April 12, 2011
Family Planning: Succeeding in Meeting Needs To Make a Better World Amy Tsui April 12, 2011 Family Planning, One of the Ten Best Public Health Achievements of the 20 th Century and Now Remarkable health
More informationCONTRACEPTIVE SOCIAL MARKETING STATISTICS
2016 CONTRACEPTIVE SOCIAL MARKETING STATISTICS August 2017 CONNECT WITH US Courtesy of DKT International 1701 K Street, NW Suite 900 Washington DC 20006 SOCIAL MARKETING STATISTICS 2016 Highlights 2016
More informationCONTRACEPTIVES SAVE LIVES
CONTRACEPTIVES SAVE LIVES Updated with technical feedback December 2012 Introduction In the developing world, particularly in Sub-Saharan Africa and South Asia, progress in reducing maternal and newborn
More informationDoes your family planning program need a Reality Check? Leah Jarvis, MPH Program Associate for Monitoring, Evaluation, and Research
Does your family planning program need a Reality Check? Leah Jarvis, MPH Program Associate for Monitoring, Evaluation, and Research Objectives By the end of the session, participants will be able to: Recognize
More informationGlobal Resources Required to Expand Family Planning Services in Low- and Middle-Income Countries. John Stover, Eva Weissman, September 2010 John Ross
Global Resources Required to Expand Family Planning Services in Low- and Middle-Income Countries John Stover, Eva Weissman, September 2010 John Ross Purpose and Approach Purpose To understand the resources
More informationContraceptives and Condoms for Family Planning and STI & HIV Prevention EXTERNAL PROCUREMENT SUPPORT REPORT
Contraceptives and Condoms for Family Planning and STI & HIV Prevention EXTERNAL PROCUREMENT SUPPORT REPORT 2013 This report is prepared by Dr. Kabir Ahmed and Dr. Sukanta Sarker of the UNFPA Commodity
More informationPMA2020: Progress & Opportunities for Advocacy AFP Partners Meeting & Gates Institute 15 th Anniversary Event
Bill & Melinda Gates Institute for Population and Reproductive Health PMA2020: Progress & Opportunities for Advocacy AFP Partners Meeting & Gates Institute 15 th Anniversary Event May 21, 2014 PMA 2020
More informationBayer Press Conference ICFP 2016, Jan 27 Bayer s Commitment on the Family Planning Globally
Bayer Press Conference ICFP 2016, Jan 27 Bayer s Commitment on the Family Planning Globally Klaus Brill, Vice President, Global HealthCare Programs, Bayer Pharma AG Nuy Talib, 24, Health Extension Worker
More informationFP2020 CORE INDICATOR ESTIMATES UGANDA
FP2020 CORE INDICATOR ESTIMATES UGANDA Published November 2014 Decision-makers require accurate and timely information in order to shape interventions, take stock of progress, and, when necessary, improve
More informationANNUAL REPORT We believe in a world where every woman and girl has the right and ability to determine her own sexuality and reproductive health.
ANNUAL REPORT 2016 We believe in a world where every woman and girl has the right and ability to determine her own sexuality and reproductive health. 22 MILLION UNSAFE ABORTIONS EACH YEAR WE RE WORKING
More informationContraceptive Technology Update And is there an Unfinished Agenda? 2011 International Conference on FP December 1, 2011
Contraceptive Technology Update And is there an Unfinished Agenda? 2011 International Conference on FP December 1, 2011 Jeff Spieler Senior Technical Advisor for Science and Technology Office of Population
More informationCONTRACEPTIVE SOCIAL MARKETING STATISTICS
2016 CONTRACEPTIVE SOCIAL MARKETING STATISTICS August 2017 CONNECT WITH US Courtesy of DKT International 1701 K Street, NW Suite 900 Washington DC 20006 SOCIAL MARKETING STATISTICS 2016 Highlights 2016
More informationFP2020 Expert Advisory Community Webinar
FP2020 Expert Advisory Community Webinar Oct. 24, 2017 www.familyplanning2020.org #FP2020Progress @FP2020Global Facebook.com/familyplanning2020 AGENDA Welcome Key Updates: 2017 Family Planning Summit to
More informationHormonal contraception and HIV risk
Hormonal contraception and HIV risk Jared Baeten, MD, PhD Departments of Global Health, Medicine, and Epidemiology, University of Washington On behalf of the ECHO Consortium HPTN Annual Meeting Washington
More informationAboubacar Kampo Chief of Health UNICEF Nigeria
Aboubacar Kampo Chief of Health UNICEF Nigeria Many thanks to UNICEF colleagues in Supply Division-Copenhagen and NY for contributing to this presentation Thirty-five countries are responsible for 98%
More informationPROMOTING VASECTOMY SERVICES IN MALAWI
PROMOTING VASECTOMY SERVICES IN MALAWI The Family Planning 2020 (FP2020) movement began in 2012, when more than 150 political leaders at the London Summit on Family Planning committed to provide 120 million
More informationMATERNAL, NEWBORN, AND CHILD HEALTH
MATERNAL, NEWBORN, AND CHILD HEALTH SESSION OBJECTIVES Introduction to GHSC-PSM Maternal, Newborn, and Child Health (MNCH) strategy and priorities Defining MNCH commodities Overview of historical and current
More informationTo Tie the Knot or Not: A Case for Permanent Family Planning Methods
To Tie the Knot or Not: A Case for Permanent Family Planning Methods Presented at the GH Mini-University Washington, D.C., October 8, 2010 By Lynn Bakamjian, MPH Project Director, RESPOND/EngenderHealth
More informationCONTRACEPTIVE SOCIAL MARKETING STATISTICS
2017 CONTRACEPTIVE SOCIAL MARKETING STATISTICS September 2018 CONNECT WITH US Courtesy of DKT International 1701 K Street, NW Suite 900 Washington DC 20006 SOCIAL MARKETING STATISTICS 2017 Highlights 2017
More informationINTRODUCING THE PROGESTERONE CONTRACEPTIVE VAGINAL RING IN SUB-SAHARAN AFRICA
SEPTEMBER 2016 project brief INTRODUCING THE PROGESTERONE CONTRACEPTIVE VAGINAL RING IN SUB-SAHARAN AFRICA Research supports the introduction of the Progesterone Vaginal Ring (PVR), a user-controlled method
More informationThe Private Sector: Key to Achieving Family Planning 2020 Goals
The Sector: Key to Achieving Family Planning 2020 Goals As family planning stakeholders look to accelerate progress toward Family Planning 2020 goals, the private health sector presents a significant opportunity
More informationSourcing of ARVs & HIV diagnostics. Procurement for Impact P4i
Sourcing of ARVs & HIV diagnostics Procurement for Impact P4i AMDS ANNUAL STAKEHOLDERS AND PARTNERS MEETING 29 September 2014 Global Fund: Procurement for Impact: P4i Our objective was straightforward:
More informationINVESTING IN A NEW FINANCING MODEL FOR THE SUSTAINABLE DEVELOPMENT ERA
Photo by Dominic Chavez INVESTING IN A NEW FINANCING MODEL FOR THE SUSTAINABLE DEVELOPMENT ERA Private Sector Engagement in the Global Financing Facility in Support of Every Woman Every Child 1 www.globalfinancingfacility.org
More information2015 CONTRACEPTIVE SOCIAL MARKETING STATISTICS
2015 CONTRACEPTIVE SOCIAL MARKETING STATISTICS November 2016 CONNECT WITH US Courtesy of DKT International 1701 K Street, NW Suite 900 Washington, DC 20006 1 SOCIAL MARKETING STATISTICS 2015 Highlights
More informationImplants and ART: weighing the evidence to guide programs
Implants and ART: weighing the evidence to guide programs Presented by: Jennifer Mason, MPH; Tabitha Sripipitana, MPH; and Sarah Yeiser, MPH Office of Population & Reproductive Health, USAID Office of
More informationSayana Press Introduction In Senegal: Strategies, Opportunities and Challenges
Sayana Press Introduction In Senegal: Strategies, Opportunities and Challenges Dr Papa Chimère Diaw Head of Family Planning Division Ministry of Health of Senegal Family Planning in Senegal Population:
More informationCOMMUNICATIONS TOOLKIT
Dominic Chavez/ FP2020 COMMUNICATIONS TOOLKIT 1 OVERVIEW FP2020 will launch its second progress report, Partnership in Progress, on November 3, 2014 in London, UK. The report details accomplishments over
More informationFP: What s New, What s Hot, and What Does It Mean for LAC
FP: What s New, What s Hot, and What Does It Mean for LAC Roy Jacobstein, MD, MPH EngenderHealth USAID LAC HPN Officers SOTA Miami, Florida March 9, 2010 Part I. Context for FP in LAC: High CPR, but outliers
More informationThe What-nots and Why-nots of Unmet Need for FP Global Health Mini-University, September 14, 2012
The What-nots and Why-nots of Unmet Need for FP Global Health Mini-University, September 14, 2012 Scott Radloff, USAID Roy Jacobstein, EngenderHealth Modern contraceptive use worldwide increased 5-fold
More informationU.S. Funding for International Family Planning & Reproductive Health
April 2016 Issue Brief U.S. Funding for International Family Planning & Reproductive Health SUMMARY The U.S. government has supported international family planning and reproductive health (FP/RH) efforts
More informationMSI experiences of Task Sharing tubal ligation by clinical officers in Zambia and Uganda
MSI experiences of Task Sharing tubal ligation by clinical officers in Zambia and Uganda Background to Zambia study Modern CPR among married women in Zambia: 33% Unmet need for family planning: 27% Unmet
More informationREPRODUCTIVE, MATERNAL, NEWBORN AND CHILD HEALTH (RMNCH) GLOBAL AND REGIONAL INITIATIVES
Information Brief: REPRODUCTIVE, MATERNAL, NEWBORN AND CHILD HEALTH (RMNCH) GLOBAL AND REGIONAL INITIATIVES Family Care International (FCI) developed this information brief as part of the Mobilising Advocates
More informationPneumococcal Conjugate Vaccine: Current Supply & Demand Outlook. UNICEF Supply Division
Pneumococcal Conjugate Vaccine: Current Supply & Demand Outlook UNICEF Supply Division Update: October 2013 0 Pneumococcal Conjugate Vaccine (PCV) Supply & Demand Outlook October 2013 Update Key updates
More informationGlobal Malaria Initiative
Global Malaria Initiative Appeal No. MAA00031 21/04/2009 This report covers the period 01/01/2008 to 31/12/2008. Volunteers from the Madagascar Red Cross participate in malaria behaviour change communication
More informationKeywords: family planning, commodities, replacement-level fertility, ethiopia. GJHSS-H Classification: FOR Code:
Global Journal of HUMANSOCIAL SCIENCE: H Interdisciplinary Volume 17 Issue 2 Version 1.0 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online ISSN:
More informationSECTION 03. Potential image caption text. Orrori re ipsam hit verum labor molupta consequias peliquos ulparch iliat.
SECTION 03 Potential image caption text. Orrori re ipsam hit verum labor molupta consequias peliquos ulparch iliat. 30 Expanding Access to Voluntary Family Planning 31 GOAL, COST, AND PROJECTED IMPACTS
More informationBill & Melinda Gates Institute for Population and Reproductive Health
Bill & Melinda Gates Institute for Population and Reproductive Health www.gatesinstitute.org Main office: W4041 Tel: 410-955-2232 Email: gatesinstitute@jhu.edu 2 www.gatesinstitute.org Vision We envision
More informationResults Based Advocacy to Increase Access Marie Stopes International
to Increase Access Marie Stopes International Women don t lease their bodies from the state or church, they own them. Founder, Tim Black (1937 2014) Almost all of the health services we provide throughout
More informationContraceptive. Ready Lessons II. What Can a Contraceptive Security Champion Do?
Contraceptive Lesson Security Ready Lessons II Expand client choice and contraceptive security by supporting access to underutilized family planning methods. What Can a Contraceptive Security Champion
More informationAccess to reproductive health care global significance and conceptual challenges
08_XXX_MM1 Access to reproductive health care global significance and conceptual challenges Dr Lale Say World Health Organization Department of Reproductive Health and Research From Research to Practice:
More informationALL LIVES HAVE EQUAL VALUE
ALL LIVES HAVE EQUAL VALUE Global Health Product Development Challenges and Opportunities IQ Symposium, Oct 5, 2016 Niya Bowers Senior Program Officer, CMC, Integrated Development 2015 Bill & Melinda Gates
More informationHormonal contraceptive methods & HIV acquisition in women: updated systematic review of epidemiological evidence
Hormonal contraceptive methods & HIV acquisition in women: updated systematic review of epidemiological evidence CHELSEA B. POLIS, PHD SEPTEMBER 16, 2016 AVAC WEBINAR GUTTMACHER INSTITUTE 2016 Acknowledgements
More informationStephanie Freid-Perenchio photography/sfp STUDIO fp2020 IN ACTION. Communications toolkit
PROGRESS REPORT 2012-2013 fp2020 PARTNERSHIP IN ACTION Communications toolkit Stephanie Freid-Perenchio photography/sfp STUDIO 1 #FP2020Progress Overview FP2020 will launch its first progress report on
More informationCOLD CHAIN EQUIPMENT OPTIMISATION PLATFORM (CCEOP)
COLD CHAIN EQUIPMENT OPTIMISATION PLATFORM (CCEOP) Sushila Maharjan Senior Manager, Innovative Finance International Conference on Sustainable Cooling World Bank Washington DC - 29 November 2018 Reach
More informationAt a glance. 16 million adolescent girls between 15 and 19 are mothers every year
At a glance 16 million adolescent girls between 15 and 19 are mothers every year Adolescent pregnancies are most common among poor and less educated girls and those living in rural areas Despite progress,
More informationNelly Mugo, MBChB, MMed, MPH Kenya Medical Research Institute. May 2015
Nelly Mugo, MBChB, MMed, MPH Kenya Medical Research Institute May 2015 Outline Rationale for the trial Design and objectives Contraceptive methods to be evaluated Study population and follow-up Potential
More informationWhat it takes: Meeting unmet need for family planning in East Africa
Policy Brief May 2018 What it takes: Meeting unmet need for family planning in East Africa Unmet need for family planning (FP) exists when a woman who wants to postpone pregnancy or stop having children
More informationThe London FP Summit Commitments
The London FP Summit Commitments A presentation by Jotham Musinguzi, MD, MPH Regional Director, PPD Africa Regional Office September 30, 2014 1 London FP Summit, July 11, 2012 In July 2012, partners from
More informationUpdate from the GAVI Alliance Seth Berkley, MD Chief Executive Officer
Update from the GAVI Alliance Seth Berkley, MD Chief Executive Officer SAGE meeting Geneva, 8-10 November 2011 Topics to cover Update on new vaccine introduction Introductions New approvals Co-financing
More informationNigeria: 2015 FPwatch Outlet Survey
Photo credit: Damien Schumann, PSI Nigeria: 2015 FPwatch Outlet Survey www.fpwatch.info Presentation Outline FP2020 and Nigeria 3 Family planning commitment & key 4-9 strategies The FPwatch Project 10
More informationPPFP Global Meeting Follow-up Workshop. Country Posters
PPFP Global Meeting Follow-up Workshop Country Posters Afghanistan Trained 12 family planning trainers in PPFP/PPIUD and developed plans to train 115 health care providers from 23 provinces in 4 regions
More informationPutting the recommendations into action
24 May, 2012 Putting the recommendations into action Dr Flavia BUSTREO Assistant Director General, Family, Women s and Children s Health Cluster on behalf of the multi-stakeholder implementation team The
More information2006 CONTRACEPTIVE SOCIAL MARKETING STATISTICS
2006 CONTRACEPTIVE SOCIAL MARKETING STATISTICS August 2007 Courtesy of DKT International 1701 K Street, NW Suite 900 Washington, DC 20006 www.dktinternational.org 1 SOCIAL MARKETING STATISTICS 2006 Highlights
More information2002 CONTRACEPTIVE SOCIAL MARKETING STATISTICS
2002 CONTRACEPTIVE SOCIAL MARKETING STATISTICS Courtesy of DKT International 1120 19th Street, NW Suite 610 July 2003 Washington, DC 20036 1 SOCIAL MARKETING STATISTICS 2001 Highlights 2002 2001 2000 CYPs
More informationJadelle Levonorgestral Rod Implants: Profile and Lessons
Jadelle Levonorgestral Rod Implants: Profile and Lessons John W. Townsend PhD Katherine Williams MHS LA/PM Community of Practice Meeting Washington DC June 23, 2009 Client Needs and Program Challenges
More informationSubcutaneous DMPA: Evidence, experience, and resources for introduction
Subcutaneous DMPA: Evidence, experience, and resources for introduction Webinar October 3, 2017 Kaitlin Christenson, MPH Siri Wood, MIA Allen Namagembe, MSc Jane Feinberg, MPA PATH/Will Boase Today s speakers
More information1. The World Bank-GAVI Partnership and the Purpose of the Review
1. The World Bank-GAVI Partnership and the Purpose of the Review 1.1 The new World Bank Group strategy makes a strong case for an expanded World Bank Group role in global and regional dialogue and collective
More informationBill & Melinda Gates Institute for Population and Reproductive Health
Bill & Melinda Gates Institute for Population and Reproductive Health Using new technologies to track access, choice, and quality dimensions of service delivery Accountability Workshop, EuroNGO Conference
More informationHow Family Planning Saves the Lives of Mothers and Children and Promotes Economic Development
ZIMBABWE How Family Planning Saves the Lives of Mothers and Children and Promotes Economic Development Ministry of Health and Child Care Zimbabwe National Family Planning Council Zimbabwe Cover photo:
More informationThe Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial
The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial A Multi-Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence and Contraceptive Benefits in Women using Depot Medroxyprogesterone
More informationPERFORMANCE MONITORING AND ACCOUNTABILITY 2020
PERFORMANCE MONITORING AND ACCOUNTABILITY 2020 Progress Report November 2015 Bill & Melinda Gates Institute for Population and Reproductive Health A Message from the Director Scott Radloff, PhD Director,
More informationImproving maternal health and access to contraceptives: pharmaceutical companies contribution to MDG 5
The Access to Medicine Index 2014 Improving maternal health and access to contraceptives: pharmaceutical companies contribution to MDG 5 Landscape Study 9 April, 2015 Pharmaceutical companies operationalise
More informationimpact dashboard year-end with 2017 coefficients
impact dashboard - 2017 year-end with 2017 coefficients In 2017, PSI averted an estimated 30.5 million DALYs and provided 20 million CYPs globally. PSI met global 2017 program targets for DALYs averted
More informationFill the Nutrient Gap Analysis: An introduction. Giulia Baldi, MPH WFP, Nutrition Division
Fill the Nutrient Gap Analysis: An introduction Giulia Baldi, MPH WFP, Nutrition Division 2 Meeting nutrient requirements is a prerequisite for preventing malnutrition MALNUTRITION Inadequate dietary intake
More informationPublic-private partnership approaches for scaling up zinc with ORS
Public-private partnership approaches for scaling up zinc with ORS Presenter: Vicki MacDonald, Abt Associates June 4, 2014 SHOPS is funded by the U.S. Agency for International Development. Abt Associates
More information2016 FP2020 ANNUAL COMMITMENT UPDATE QUESTIONNAIRE RESPONSE
MYANMAR HTTP://WWW.FAMILYPLANNING2020.ORG/MYANMAR In July 2016, the government of Myanmar shared the following update on progress toward achieving its Family Planning 2020 commitment during the 2015-2016
More informationReport on MCSP Support for the Polio Switch in April 2016
Report on MCSP Support for the Polio Switch in April 2016 www.mcsprogram.org Report date: September 1, 2016 This report is made possible by the generous support of the American people through the United
More informationMobile clinic services will be provided along with a campaign for long term and new methods of family planning in Afghanistan
Afghanistan Satellite Event: I Decide Art Competition I Decide campaign art competition with young artists Host(s):Afghan Family Guidance Association Afghanistan Satellite Event: Mobile Clinic SRHR Services
More informationWHO Global Task Force on TB Impact Measurement An overview
WHO Global Task Force on TB Impact Measurement An overview Katherine Floyd (WHO/GTB/TME) 3 rd meeting of the TB estimates subgroup Glion-sur-Montreux, 31March 2 April 2015 GLOBAL TB PROGRAMME 1. Broad
More informationThe Bill and Melinda Gates Institute for Population and Reproductive Health
The Bill and Melinda Gates Institute for Population and Reproductive Health www.jhsph.edu/gatesinstitute Main office: W4041 Tel: 410-955-2232 Email: gates@jhsph.edu Mission To strengthen the capacity of
More informationIntroduction to the Family Planning Financing Roadmap
Introduction to the Family Planning Financing Roadmap ATTAINING SUSTAINABLE FINANCING FOR FAMILY PLANNING IN SUB-SAHARAN AFRICA ACCRA, JANUARY 2018 Catherine Barker Cantelmo 1 Website Purpose Create an
More informationTHE FAMILY PLANNING SUMMIT FOR SAFER, HEALTHIER AND EMPOWERED FUTURES
THE FAMILY PLANNING SUMMIT FOR SAFER, HEALTHIER AND EMPOWERED FUTURES Overview In July 2012, leaders from around the world gathered in London for a watershed event. The London Summit on Family Planning
More informationRenewing Momentum in the fight against HIV/AIDS
2011 marks 30 years since the first cases of AIDS were documented and the world has made incredible progress in its efforts to understand, prevent and treat this pandemic. Progress has been particularly
More informationUpdate on progress of MPP sublicensees
Update on progress of MPP sublicensees Medicines Patent Pool SEPTEMBER 2018 SUMMARY This presentation showcases the progress made by MPP licensees (generic pharmaceutical companies) To date, MPP has signed
More informationWorld Food Programme (WFP)
UNAIDS 2016 REPORT World Food Programme (WFP) Unified Budget Results and Accountability Framework (UBRAF) 2016-2021 2 Contents Achievements 2 Introduction 2 Innovative testing strategies 2 Access to treatment
More informationDiagnostic Procurement The Clinton Foundation HIV/AIDS Initiative
Diagnostic Procurement The Clinton Foundation HIV/AIDS Initiative 28 October 2008 Geneva 1 CHAI Work in Diagnostics - Context Diagnostic Test Agreements - In 2002 when CHAI was formed, the price of many
More informationAn overview of DMPA-SC: A new type of injectable contraception that expands access and options
TOOL 1 This page is for instructional use only. When printing this tool in Adobe Acrobat, please start your printing with page 2, unless you mean to print this page. An overview of DMPA-SC: A new type
More information2 Background EXPANDING CONTRACEPTIVE ACCESS AND OPTIONS
SUBCUTANEOUS DMPA INTRODUCTION: PRACTICAL GUIDANCE FROM PATH 2 Background PATH/Will Boase The introduction of subcutaneous DMPA (DMPA-SC, brand name Sayana Press) promises to expand women s access to family
More informationTB Disease Prevalence Survey - Progress Report
TB Disease Prevalence Survey - Progress Report 30 Oct 2011, Lille Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force on TB Impact Measurement Stop TB Department, WHO onozakii@who.int
More informationThe World Bank: Policies and Investments for Reproductive Health
The World Bank: Policies and Investments for Reproductive Health Sadia A Chowdhury Coordinator, Reproductive and Child Health, The World Bank Bangkok, Dec 9, 2010 12/9/2010 2 Maternal Mortality Ratio (MMR):
More informationDonor Support for Contraceptives and Condoms for STI/HIV Prevention 2009
Donor Support for Contraceptives and Condoms for STI/HIV Prevention 2009 Acknowledgements UNFPA is grateful for all of the invaluable contributions to this report, which would not have been possible without
More informationUSG Update on Family Planning/HIV Integration
USG Update on Family Planning/HIV Integration Nithya Mani, USAID/Office of HIV/AIDS Jennifer Mason, USAID/Office of Population and Reproductive Health IAWG SRH and HIV Linkages Meeting March 9-10, 2015
More informationFunding for AIDS: The World Bank s Role. Yolanda Tayler, WB Bi-regional Workshop for the Procurement of ARVs Phnom Penh, Cambodia
Funding for AIDS: The World Bank s Role Yolanda Tayler, WB Bi-regional Workshop for the Procurement of ARVs Phnom Penh, Cambodia Outline New resources needs estimates Bridging the gap Global overview of
More informationIX. IMPROVING MATERNAL HEALTH: THE NEED TO FOCUS ON REACHING THE POOR. Eduard Bos The World Bank
IX. IMPROVING MATERNAL HEALTH: THE NEED TO FOCUS ON REACHING THE POOR Eduard Bos The World Bank A. INTRODUCTION This paper discusses the relevance of the ICPD Programme of Action for the attainment of
More informationimpact dashboard - june 2018
impact dashboard - june 2018 As of June, PSI averted an estimated 11.3 M DALYs, provided 8.1 M CYPs, and reached 12.5 M users globally. Ethiopia, Zambia, and Cameroon have made considerable progress on
More informationDEPARTMENT OF INTERNATIONAL HEALTH
DEPARTMENT OF INTERNATIONAL HEALTH he Health Systems Program is a global leader in research, teaching, and strategic collaborations focused on achieving accessible, costeffective health care and healthy
More informationThe Role of Family Planning in Meeting MDGs
The Role of Family Planning in Meeting MDGs Pamela Foster, Isaiah Ndong, Roy Jacobstein, and Laura Subramanian 50th ECSA Health Ministers Conference Kampala, Uganda, 16 February, 2010 Rationales for FP:
More information